Govt Support Bolsters Pharmicell’s Stem Cell Therapy Plans
This article was originally published in PharmAsia News
Pharmicell is to kick off the development of a stem cell-based therapy for chronic kidney disease and a gene therapy for liver cancer with support from the South Korean government, which is nurturing the development of both sectors as part of a national strategic plan.
You may also be interested in...
South Korea's Pharmicell is taking steady steps towards commercializing a stem cell therapy for alcoholic liver cirrhosis, an area with outstanding needs, following a successful Phase II domestic trial that lays the ground for a Phase III program and the start of US clinical development.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.